Search
Autolus Therapeutics PLC
AUTLAdd to Watchlist
1.170USD
-0.020-1.68%
Close 11-13 16:00（ET）
311.41MMarket Cap
LossP/E TTM
Autolus Therapeutics PLC (AUTL) Stock Price Target & Forecast
Analyst Rating
Based on 10 analysts giving stock ratings to Autolus Therapeutics PLC in the past month.
Buy
4 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
8.444USD+455.56%
AUTL Analyst Recommendation Trends
In the current month, AUTL has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. AUTL average Analyst price target in the last month is 8.444.
2026-11
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
4
4
4
4
4
4
4
4
6
6
6
6
7
8
8
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10
10
10
10
11
12
12
12
AUTL Analyst Rating for Peer Comparison
Updated: Nov 5, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
8
16
12
1
0
37
Amgen Inc
AMGN
4
9
19
3
1
36
Vertex Pharmaceuticals Inc
VRTX
10
17
5
0
1
33
Eli Lilly and Co
LLY
10
19
3
1
0
33
Alnylam Pharmaceuticals Inc
ALNY
7
17
8
0
0
32
AbbVie Inc
ABBV
8
18
6
0
0
32
Neurocrine Biosciences Inc
NBIX
13
14
4
0
0
31
Merck & Co Inc
MRK
7
16
8
0
0
31
Gilead Sciences Inc
GILD
7
18
5
0
0
30
Bristol-Myers Squibb Co
BMY
5
6
18
1
0
30
Financial Forecasting
Based on analysts' estimates, AUTL EPS is projected to reach -0.170 in FY2026Q4, following reported EPS of -0.207 in FY2026Q3. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
FY2027Q1
Forecast
-0.26
-0.22
-0.16
-0.17
-0.16
Actual
-0.27
-0.15
-0.21
--
--
Surprise
-4.62%
+31.88%
-27.86%
--
--
FAQs
What is Autolus Therapeutics PLC's expected revenue for the next quarter?
Autolus Therapeutics PLC's expected revenue is 38.15M.
What is Autolus Therapeutics PLC's price target?
Analysts forecast that Autolus Therapeutics PLC's price target is USD 8.44, with the highest forecast at USD 11.00 and the lowest forecast at USD 5.00.
How have Autolus Therapeutics PLCAUTL's recent earnings per share performed?
The market expectation was USD -0.21, while Autolus Therapeutics PLCAUTL's earnings per share (EPS) for the previous quarter was USD -0.15. EPS for the next quarter is expected at USD -0.17.
What is the analyst rating for Autolus Therapeutics PLC?
Based on the ratings of Autolus Therapeutics PLC's stock from 10 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.